ClinicalTrials.gov
public full text
Public Domain
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure. Participants in the study will be treated with either a study drug plus current standard of care (SOC), or with placebo plus current SOC. Substudy H1: Aviptadil for Severely Ill Inpatients With COVID-19 (NCT06729606) Substudy H2: Remdesivir for Severely Ill Inpatients With COVID-19 (NCT06729593)
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)#1126782
- Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus#969098
- The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients#1369901
- Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial#1259764
- Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o.#879220
Record · ID 1445558
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive